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Upper vs. lower extremity: Does the site of 
steroid injection have a different effect on 
blood glucose levels in patients with 
diabetes? 
EMILYN ANDERI, MS, Wayne State University School of Medicine, gc5844@wayne.edu 
 
ABSTRACT A clinical decision report appraising Twu J, Patel N, Wolf JM, Conti Mica M. Impact of variation of corticosteroid 
dose, injection site, and multiple injections on blood glucose measurement in diabetic patients. J Hand Surg Am. 2018;43(8):738-
744. https://doi.org/10.1016/j.jhsa.2018.06.005 for a patient with diabetes and osteoarthritis.  
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Clinical Context 
Ryan Carpenter (pseudonym), a 63-year-old Caucasian male with a history of type 2 diabetes mellitus and 
osteoarthritis (OA) of bilateral knee joints, presented to his family medicine clinic with a complaint of increasing 
knee pain. When he was first diagnosed with OA, Mr. Carpenter was able to find relief with NSAIDs and physical 
therapy, however, as time went on this relief became less and less, and his daily activities were becoming severely 
affected. Upon review of his radiographic findings, severe joint space narrowing and cartilage damage of both 
knees was visible. Although Mr. Carpenter understood intra-articular steroid was not a long-term therapy, he was 
only interested in improving his function over the next month with the many activities planned for his daughter’s 
wedding. Due to his increasing pain, the option of a glucocorticoid injection for short-term relief was presented to 
Mr. Carpenter. Consideration of the effects the glucocorticoid injection would have on his blood glucose took 
place. Mr. Carpenter stated that he had no issues with his blood glucose when he received a similar type of 
injection for a frozen shoulder many years ago, but since that time, his diabetes has been more difficult to control, 
requiring addition of dual oral therapy and low dose long acting insulin at bedtime. He currently has good diabetic 
control but agreed to monitor his blood glucose more carefully for 2 weeks following the procedure, particularly 
because the planned social events are often accompanied by “celebratory” foods not in his usual diet. 
Clinical Question 
Does an intra-articular glucocorticoid injection in a lower extremity have a greater effect on the blood glucose levels compared to an 
injection of an upper extremity in patients with diabetes mellitus? 
ANDERI E. Upper vs. lower extremity: Does the site of steroid injection have a different effect on blood 
glucose levels in patients with diabetes? Clin. Res. Prac. Oct 16 2020;6(2):eP2291. 
https://doi.org/10.22237/crp/1593562200 
 






http://digitalcommons.wayne.edu/crp, © 2020 The Author(s) 
2 Licensed under Creative Commons Attribution 4.0 International (CC-BY-4.0) 
 
Research Article 
Twu J, Patel N, Wolf JM, Conti Mica M. Impact of variation of corticosteroid dose, injection site, and multiple injections on blood 
glucose measurement in diabetic patients. J Hand Surg Am. 2018;43(8):738-744. https://doi.org/10.1016/j.jhsa.2018.06.005. 
Related Literature 
A review of UpToDate was initially performed to evaluate the current management of patients with moderate to severe OA, as well 
as the comorbidities that impact the management.1,2 Currently, the management of OA involves both pharmaceutical and non-
pharmaceutical modalities, aimed around reducing inflammation and physical therapy. While intra-articular glucocorticoid injections 
are not routinely used for patients with knee OA, their use can provide some short-term relief to patients with moderate to severe 
OA.1 For patients with diabetes, glucocorticoid injections can produce a transient hyperglycemia, and therefore it is advised that 
patients monitor their blood glucose for a few days post-injection.2 
A subsequent search of PubMed was performed using the terms “diabetic” AND “joint injection” AND “blood glucose” returned 33 
results. The titles and abstracts were reviewed to find publications relevant to the clinical question. This further refined the results 
to 15 articles. Of these results, 2 were systematic reviews and 5 were clinical trials. The titles and abstracts of these 21 results were 
used to determine relevance in relation to the clinical question.  
One article discussed the impact of intra-articular betamethasone injections for diabetic patients.3 However this study focused on 
the impact on insulin resistance not blood glucose levels and therefore was omitted. Another looked at the impact of 
methylprednisolone acetate on fructosamine levels, but again was omitted as it did not pertain directly to the clinical question.4  
A publication by Zufferey et al. studied the effects of epidural steroid injections on blood glucose in patients with diabetes mellitus 
and found that there was no significant increase in blood glucose levels post-intervention.5 This paper found conflicting results with 
one published by Younes et al., but brought up the discussion of how glycemic effects could differ based on the type of steroid used 
(soluble versus depot type).6 However, because these papers addressed the use of epidural injections, not intra-articular, they were 
deemed less relevant to the clinical question.  
Two systematic reviews discussed the systemic effects of intra-articular glucocorticoid injections in diabetic patients.7-8 Both 
provided insight as to other effects that may need to be considered when a glucocorticoid injection is offered to a diabetic, but were 
considered too broad in relation to the clinical question.  
There are many articles are available discussing the changes in blood glucose after shoulder injections, where the overall consensus 
is that there is no significant increase in blood glucose levels.9-11 There was also an article that noted a significant increase in blood 
glucose  after knee injections.12 While these articles could all be considered relevant to the clinical question, there was one study 
that directly compared upper versus lower extremity injections and their effects on blood glucose. Utilizing the Twu et al. paper, the 
comparison of upper versus lower extremity and effect on blood glucose could be directly answered, and therefore was the paper 
chosen to analyze.13 Given the above sources discussed, this body of evidence is a Grade-B Strength of Recommendation based on 
the SORT criteria. 
Critical Appraisal 
The article by Twu et al. is a prospective cohort study to monitor the effects on blood glucose of 60 patients with diabetes mellitus 
who were offered a corticosteroid injection for either an upper or lower joint injection. Patients had to have a documented diagnosis 
of diabetes mellitus, be above the age of 18, able to complete glucose measurements, and not have received any injections in the 
past 3 months to be included in the study. Once enrolled, patients received standard injections of triamcinolone based on their 
assigned injection site, and were given a log to record one fasting and one 2-hour postprandial blood glucose measurement for 14 
days post-injection. Upon completion of the 14 days, researchers contacted study participants to retrieve measurement data. Based 
on this study design, this article is considered to have a SORT evidence level of 3.  
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Table 1 in the article outlines the demographics and baseline characteristics of patients who received different injections. Patients 
were separated into 3 groups based on the type of injection they were receiving; a single upper extremity injection (n=32), a single 
lower extremity injection (n=17), or multiple injections (n=11). These patients were approached to join the study based on their 
diagnosis and treatment offered. Because of this, the study may present with selection bias. As well, the groups were assigned based 
on documented injection needed, therefore there was no randomization amongst study groups.  
It can also be noted that there were some baseline differences between groups. In particular, the average HbA1C varied from 7.65 
for patients receiving an upper extremity injection, 7.45 for lower extremity, and 7.6 for multiple injections. Our patient was a 63 
year old male receiving a lower extremity injection, with an HbA1C of 7.2. This would indicate that his diabetes was slightly better 
controlled than then average patient receiving the same injection as him in the study.  
Each group received a separate experimental intervention depending on their study group. Since each type of injection requires a 
specific amount of steroid, patients receiving an upper extremity injection received less steroid than someone requiring a lower 
extremity injection. This difference in steroid dose could have accounted for some of the differences seen in blood glucose changes 
post-injection. However, aside from the differences in intervention, all study groups followed the same experimental protocol.  
A mixed-model covariant analysis was used to interpret the significance of the changes in fasting and postprandial blood glucose, 
which accounted for day-to-day measurements, corticosteroid dose, single versus multiple injections, BMI, insulin use, and HbA1C. 
This allowed for the use of both fixed effects, like how groups differ between a set of treatments, and random effects, such as the 
variability among study subjects. The entire cohort was analysed together, followed by analysis of each group separately.  
The outcome was based on a comparison of days 1-7 compared to days 10-14, with the later days considered “baseline” on the 
assumption that a change in blood glucose would only occur within the first week. Changes in blood glucose were the highest on day 
1—elevated by 35 mg/dl, a clinically meaningless difference. In fact, when reviewing the methodology and the outcomes chosen by 
the researchers, this article seems to report trivial findings. The usefulness of the evidence is that there was not a bad outcome in 
any patient, which could be used to reassure Mr. Carpenter. 
Clinical Application 
Glucocorticoid injections are an effective treatment for a variety of upper and lower extremity joint conditions 
such as osteoarthritis. However, these steroids have been shown to affect glucose metabolism, and cause 
abnormal blood glucose measurements in diabetics. This raises the concern of many different glucose-related 
complications, such as diabetic ketoacidosis, that could arise if diabetics receive an intra-articular injection. The 
findings by Twu et al. suggest that the location of injection (upper versus lower extremity) does play a role in the 
differences of post-injection blood glucose measurements for patients with diabetes mellitus. While all patients 
did see some increase in both fasting and postprandial blood glucose levels up to 72 hours post-injection, this 
increase was not significant for patients who received upper extremity injections or multiple injections. However, 
patients who received lower extremity injections were found to have a statistically significant and clinically 
meaningless increase in fasting blood glucose, with no impact on postprandial blood glucose.  The study also found 
that as HbA1C increased, more significant increases in blood glucose were also seen. 
For our patient Mr. Carpenter, this study suggests that he should indeed monitor his blood glucose levels more 
closely upon receiving a glucocorticoid injection in his knee, as there may be a significant increase in the weeks 
post-injection. This study could also be used to explain why Mr. Carpenter did not raise any concern when he 
received a similar injection in his shoulder many years ago. It should be noted that Mr. Carpenter’s demographics 
did not match up perfectly with the study participants considering he had a lower HbA1C of 7.2, and is Caucasian 
(90% of study participants were of black ethnicity), and therefore this study cannot truly predict his blood glucose 
response to glucocorticoid injections. Nonetheless, we thoroughly counselled Mr. Carpenter on the importance of 
blood glucose control, and that closer monitoring of his blood glucose post-injection was encouraged. In 
practicality, his dietary consumption is a far greater risk for diabetic control, so we took the opportunity to counsel 
him on coping strategies to manage calorie intake during the upcoming festivities. Considering how prevalent 
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diabetes is, the information provided by this article does provide opportunity for discussion between physician and 
patient about the risks and benefits of receiving glucocorticoid intra-articular injections. 
New Knowledge Related to Clinical Decision Science 
Osteoarthritis and diabetes are common problems in the population. These chronic medical conditions had major impact for our 
patient, Mr. Carpenter. His OA was no longer controlled, and he needed relief for a specific short-term social activity. Our team 
proposed corticosteroid injections to provide him with some relief, but it was important for us to consider the impact it may have on 
his diabetes, which has been well-controlled. The study by Twu et al. showed that it could actually improve his diabetic control if he 
could be more physically active. Given the prevalence of both diabetes and OA in the population, discussion between the physician 
and patient in regard to the effect treatment of one disease could have on the other is an important conversation and is the 
hallmark of Clinical Decision Science.  
Should a scenario arise in which a patient with poorly controlled diabetes has uncontrolled OA, the results of the Twu et al. study 
would have a different meaning and the physician might have a different discussion about the harms and benefits of corticosteroid 
injections on their particular care. A change of 35 mg/dl in that situation (the size effect documented in this paper) may be more 
dangerous. 
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